Isamu Okamoto
#145,761
Most Influential Person Now
Researcher
Isamu Okamoto's AcademicInfluence.com Rankings
Isamu Okamotocomputer-science Degrees
Computer Science
#7291
World Rank
#7679
Historical Rank
Machine Learning
#2645
World Rank
#2680
Historical Rank
Artificial Intelligence
#2941
World Rank
#2986
Historical Rank
Database
#4353
World Rank
#4527
Historical Rank
Download Badge
Computer Science
Isamu Okamoto's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Isamu Okamoto Influential?
(Suggest an Edit or Addition)Isamu Okamoto's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) (3811)
- Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018) (2753)
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019) (836)
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. (2014) (645)
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
- Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012) (537)
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. (2014) (506)
- Human Ect2 Is an Exchange Factor for Rho Gtpases, Phosphorylated in G2/M Phases, and Involved in Cytokinesis (1999) (423)
- Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. (2013) (411)
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. (2018) (406)
- Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway (2001) (376)
- Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer (2015) (340)
- Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (335)
- CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration (1999) (273)
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. (2020) (215)
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) (2008) (205)
- Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations (2009) (197)
- Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. (2018) (177)
- FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. (2010) (167)
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors (2009) (166)
- Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. (2002) (163)
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer (2011) (162)
- Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. (2010) (159)
- Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (2012) (159)
- Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). (2010) (159)
- Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. (2007) (157)
- Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients (2008) (152)
- Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. (2016) (150)
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. (2015) (149)
- Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines (2008) (144)
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (141)
- Presenilin-dependent γ-secretase activity mediates the intramembranous cleavage of CD44 (2003) (136)
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer (2011) (131)
- Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell – cell contacts (1999) (131)
- MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations (2011) (129)
- Expression of constitutively activated EGFRvlll in non‐small cell lung cancer (2003) (128)
- Deregulation and Mislocalization of the Cytokinesis Regulator ECT2 Activate the Rho Signaling Pathways Leading to Malignant Transformation* (2004) (126)
- Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. (2016) (119)
- The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer (2013) (112)
- Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. (2007) (109)
- Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification (2011) (107)
- Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. (2003) (106)
- Elevated JNK activation contributes to the pathogenesis of human brain tumors (2002) (104)
- Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status (2008) (102)
- EGFR mutation in gefitinib-responsive small-cell lung cancer. (2006) (100)
- OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (2011) (98)
- Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer (2014) (96)
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2010) (91)
- Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 (2015) (91)
- MET amplification as a potential therapeutic target in gastric cancer (2012) (89)
- Targeting MET Amplification as a New Oncogenic Driver (2014) (88)
- Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. (2010) (84)
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset (2018) (83)
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation (2010) (82)
- CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. (2014) (81)
- Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. (2003) (80)
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor (2010) (79)
- Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset (2019) (78)
- Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. (2013) (78)
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (77)
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification (2012) (76)
- Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer (2011) (76)
- Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy (2010) (74)
- Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (2019) (72)
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. (2012) (72)
- Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement (2013) (71)
- Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib (2016) (71)
- SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion (2009) (70)
- Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011) (70)
- De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer (2010) (70)
- Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs (2010) (70)
- Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase (2008) (69)
- PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. (2018) (69)
- PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. (2018) (69)
- Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples (2015) (69)
- Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations (2016) (68)
- Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. (2013) (67)
- Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification (2010) (67)
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. (2018) (66)
- Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin (2011) (65)
- Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. (2018) (65)
- Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. (1998) (65)
- Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. (2010) (62)
- Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG (2008) (61)
- Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression (2014) (59)
- The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2014) (59)
- Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells (2009) (58)
- Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. (2011) (57)
- Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients (2016) (56)
- Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib (2014) (55)
- Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. (2018) (54)
- Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. (2013) (53)
- Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. (2003) (52)
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells (2012) (52)
- Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. (2011) (52)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. (2021) (51)
- Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification (2009) (51)
- A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer (2008) (50)
- HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer (2015) (50)
- Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. (2013) (50)
- Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial (2018) (49)
- Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk (2007) (49)
- Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition (2010) (48)
- Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results (2017) (47)
- Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. (2017) (44)
- Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. (2019) (44)
- The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer (2015) (43)
- Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms (2013) (43)
- Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer (2014) (43)
- Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer (2009) (42)
- Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. (2020) (42)
- Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. (2013) (41)
- Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. (2020) (41)
- Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. (2020) (41)
- Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. (2005) (41)
- Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis (2018) (40)
- Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations (2017) (39)
- S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) (2011) (39)
- Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. (2017) (39)
- Proteolytic release of CD 44 intracellular domain and its role in the CD 44 signaling pathway (2001) (39)
- Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. (2020) (39)
- Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer (2008) (38)
- Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. (2018) (38)
- Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. (2018) (38)
- Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification (2010) (38)
- Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. (2012) (37)
- A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis (2020) (37)
- Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib (2016) (36)
- Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (2013) (36)
- Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. (2013) (36)
- Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L (2013) (36)
- Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. (2013) (35)
- 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer (2019) (34)
- Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial (2016) (34)
- High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin (2011) (34)
- SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer (2012) (34)
- 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer (2019) (34)
- Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. (2019) (34)
- Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer. (2019) (34)
- Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer (2006) (34)
- Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors (2020) (33)
- Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer (2017) (33)
- Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors (2014) (33)
- Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. (2010) (33)
- Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors (2020) (33)
- Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study (2014) (32)
- Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer (2015) (32)
- Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (2010) (32)
- Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. (2015) (32)
- Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment (2012) (32)
- Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. (2011) (32)
- Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401) (2017) (32)
- Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells (2011) (31)
- FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib (2016) (31)
- Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. (2020) (31)
- Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. (2020) (31)
- Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. (2019) (31)
- Identification of thymidylate synthase as a potential therapeutic target for lung cancer (2010) (31)
- Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. (1998) (31)
- Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT) (2021) (31)
- MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy (2016) (30)
- S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. (2009) (30)
- PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. (2019) (29)
- Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study. (2021) (29)
- Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. (2017) (29)
- The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations (2010) (28)
- Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. (2019) (28)
- Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. (2019) (28)
- Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor. (2012) (28)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study (2021) (28)
- Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR (2015) (28)
- Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer (2014) (27)
- Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. (2012) (27)
- Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma (2013) (27)
- A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G). (2011) (27)
- Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. (2016) (26)
- Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. (2016) (26)
- Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). (2019) (26)
- Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. (2012) (26)
- Amrubicin for non-small-cell lung cancer and small-cell lung cancer (2007) (26)
- Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events (2021) (26)
- Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. (2005) (26)
- First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting (2019) (25)
- Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement. (2014) (25)
- Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 (2008) (24)
- Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. (2020) (24)
- Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. (2019) (24)
- Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. (2018) (24)
- Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience (2007) (24)
- Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. (2020) (24)
- Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients (2006) (24)
- CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (2017) (23)
- Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. (2010) (23)
- Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing (2018) (23)
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (2014) (23)
- Sorting nexin 2‐mediated membrane trafficking of c‐Met contributes to sensitivity of molecular‐targeted drugs (2013) (23)
- Intrinsic and Extrinsic Regulation of PD‐L2 Expression in Oncogene‐Driven Non–Small Cell Lung Cancer (2018) (23)
- CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. (2017) (22)
- Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. (2017) (22)
- Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment (2013) (22)
- Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. (2019) (22)
- Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset (2018) (22)
- Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. (2017) (22)
- Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. (2018) (22)
- Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. (2018) (22)
- The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer (2021) (21)
- Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients (2019) (21)
- Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. (2014) (21)
- Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors (2011) (21)
- The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo (2007) (21)
- LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study (2022) (21)
- Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples (2015) (21)
- Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. (2013) (21)
- Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8–10/CD44v10 competitive RT‐PCR (1998) (21)
- Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement. (2012) (21)
- Induction of PD-L 1 Expression by the EML 4 – ALK Oncoprotein andDownstreamSignalingPathways in Non – Small Cell Lung Cancer (2015) (21)
- Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis (2019) (21)
- Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting (2021) (20)
- Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. (2011) (20)
- Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group (2014) (20)
- Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting (2021) (20)
- The anti‐EGFR monoclonal antibody blocks cisplatin‐induced activation of EGFR signaling mediated by HB‐EGF (2008) (20)
- A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma (2019) (20)
- Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade (2018) (20)
- Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade (2018) (20)
- Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors (2009) (19)
- PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer (2018) (19)
- Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer. (2021) (19)
- Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. (2022) (19)
- A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (19)
- Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan (2008) (19)
- Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 (2019) (19)
- Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401) (2010) (19)
- Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors (2019) (19)
- Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer. (2021) (19)
- Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. (2021) (19)
- Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells. (2007) (18)
- Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. (2009) (18)
- Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. (2008) (18)
- Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis (2018) (18)
- A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
- Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer? (2006) (18)
- EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403). (2006) (18)
- Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). (2019) (17)
- Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). (2019) (17)
- Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors (2012) (16)
- Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel (2015) (16)
- Reversible posterior leukoencephalopathy syndrome and trastuzumab (2012) (16)
- Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B (2013) (16)
- Echinoderm microtubule‐associated protein‐like 4–anaplastic lymphoma kinase‐targeted therapy for advanced non‐small cell lung cancer: Molecular and clinical aspects (2012) (15)
- Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations (2022) (15)
- Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. (2017) (15)
- Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. (2019) (15)
- Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. (2019) (15)
- Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomas. (1998) (15)
- Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. (2020) (15)
- Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. (2020) (15)
- A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud (2017) (14)
- Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer. (2015) (14)
- Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). (2012) (14)
- Anticancer drug treatment for advanced lung cancer with interstitial lung disease. (2018) (14)
- Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. (2013) (14)
- Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib (2015) (14)
- A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients (2020) (13)
- Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. (2011) (13)
- 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 (2021) (13)
- Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer (2015) (13)
- Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). (2021) (13)
- Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay (2017) (13)
- Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. (2019) (13)
- Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. (2015) (12)
- Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix‐assisted laser desorption ionization mass spectrometry imaging: a pilot study (2018) (12)
- First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset (2020) (12)
- Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2020) (12)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (12)
- Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. (2018) (12)
- Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study (2020) (12)
- Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. (2010) (12)
- Clinical response to crizotinib retreatment after acquisition of drug resistance. (2013) (12)
- Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer (2018) (12)
- Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement (2015) (12)
- Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay (2018) (12)
- Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement (2015) (12)
- Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer (2012) (12)
- Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. (2011) (12)
- Deoxyinosine triphosphate induces MLH1/PMS2- and p53-dependent cell growth arrest and DNA instability in mammalian cells (2016) (12)
- Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production. (2008) (12)
- Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC (11)
- Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor (2019) (11)
- Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae (2016) (11)
- Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer (2018) (11)
- Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed (2010) (11)
- Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis (2020) (11)
- Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression. (2012) (11)
- Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer (2013) (11)
- Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups. (2017) (11)
- Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment. (2017) (11)
- LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study (2021) (11)
- Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC (11)
- Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. (2021) (11)
- Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis (2020) (11)
- Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype (2020) (11)
- Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) (2022) (10)
- Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. (2019) (10)
- A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). (2020) (10)
- NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. (2020) (10)
- Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (2020) (10)
- Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. (2015) (10)
- NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. (2020) (10)
- 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib (2021) (10)
- CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. (2017) (9)
- Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors (2010) (9)
- OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis (2017) (9)
- Fosfomycin inhibits NF-κB activation in U-937 and Jurkat cells (2003) (9)
- Absence of gallium uptake in unicentric and multicentric Castleman's disease. (2003) (9)
- Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) (2016) (9)
- Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). (2019) (8)
- Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). (2019) (8)
- 9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 (2009) (8)
- Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives (2019) (8)
- Clinical development of nintedanib for advanced non-small-cell lung cancer (2015) (8)
- Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. (2019) (8)
- Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. (2017) (8)
- Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). (2015) (8)
- Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). (2019) (8)
- Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy (2020) (8)
- Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study. (2013) (8)
- Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. (2020) (8)
- Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) (2020) (7)
- Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors (2020) (7)
- Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy (2021) (7)
- Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples (2018) (7)
- Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer (2012) (7)
- O1-10-3Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer (2015) (7)
- Treatment Rationale and Design for J‐AXEL: A Randomized Phase 3 Study Comparing Nab‐Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small‐Cell Lung Cancer (2017) (7)
- Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung (2013) (7)
- Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial (2022) (7)
- Treatment Rationale and Design for J‐AXEL: A Randomized Phase 3 Study Comparing Nab‐Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small‐Cell Lung Cancer (2017) (7)
- Pemetrexed-induced edema of the eyelid. (2006) (7)
- Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. (2010) (7)
- LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression (2020) (6)
- A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer. (2014) (6)
- Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition (2010) (6)
- Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan (2007) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset * (2021) (6)
- Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer (2015) (6)
- A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) (2020) (6)
- 1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors (2009) (6)
- Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter (2014) (6)
- The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors (2022) (6)
- First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis (2021) (5)
- Successful treatment with alectinib after crizotinib-induced esophageal ulceration. (2015) (5)
- Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non small cell lung cancer (NSCLC). (2004) (5)
- Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer (2021) (5)
- Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. (2021) (5)
- Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis (2021) (5)
- Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer (2021) (5)
- Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma (2019) (5)
- A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study (2022) (5)
- A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study (2022) (5)
- Perirenal hematoma associated with bevacizumab treatment (2012) (5)
- Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. (2021) (5)
- 420OErlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis (2015) (5)
- Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis (2021) (5)
- Successful treatment with alectinib after crizotinib-induced esophageal ulceration. (2015) (5)
- Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors (2019) (5)
- Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (4)
- Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. (2009) (4)
- Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. (2019) (4)
- P1.18-04 Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial (2019) (4)
- Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. (2021) (4)
- Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. (2018) (4)
- Clinical outcome for EML 4-ALK-positive patients with advanced non-small-cell lung cancer treated with fi rst-line platinum-based chemotherapy (2012) (4)
- Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. (2012) (4)
- Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. (2020) (4)
- Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. (2012) (4)
- Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) (2020) (4)
- Differential roles of STAT 3 depending on the mechanism of STAT 3 activation in gastric cancer cells (2014) (4)
- Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies (2017) (4)
- Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study (2018) (4)
- The anti-HER 3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2015) (4)
- A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy plus Pembrolizumab with Platinum Combination Chemotherapy plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study) (2021) (4)
- Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. (2020) (4)
- A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (2019) (4)
- Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small-Cell Lung Cancer Cells by Targeting Survivin (2012) (4)
- Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE (2021) (4)
- Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. (2018) (4)
- Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naive patients (Pts) with advanced non-squamous non-small cell lung cancer (NSCLC). (2012) (4)
- Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer? (2003) (4)
- Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A) (2016) (3)
- Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer. (2017) (3)
- Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. (2019) (3)
- Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors. (2010) (3)
- Predictive and prognostic impact of primary tumor‐bearing lobe in nonsmall cell lung cancer patients treated with anti‐PD‐1 therapy (2020) (3)
- Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. (2017) (3)
- Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms. (2012) (3)
- Fosfomycin inhibits NF-kappaB activation in U-937 and Jurkat cells. (2003) (3)
- LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset (2017) (3)
- Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. (2019) (3)
- Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. (2019) (3)
- A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site (2013) (3)
- Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC (2019) (3)
- Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. (2014) (3)
- Neural stem cell–specific ITPA deficiency causes neural depolarization and epilepsy (2020) (3)
- Predictive and prognostic impact of primary tumor‐bearing lobe in nonsmall cell lung cancer patients treated with anti‐PD‐1 therapy (2020) (3)
- Current status and future perspectives of cooperative study groups for lung cancer in Japan. (2014) (3)
- Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer. (2020) (3)
- Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L) (2021) (3)
- Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. (2019) (3)
- The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer. (2014) (2)
- Pleuropulmonary Paragonimiasis with Multiple Nodules in the Pleura (2020) (2)
- Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. (2021) (2)
- Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. (2021) (2)
- HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors (2020) (2)
- P2.03a-056 Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: KTOSG Trial 1301: Topic: Clinical Trials (2017) (2)
- Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) (2022) (2)
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial (2023) (2)
- P3-151: EGFR mutation–based phase II multicenter trial of gefitinib in patients with advanced non–small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0403) (2007) (2)
- Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC). (2019) (2)
- 9044 POSTER Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy (CRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) (2011) (2)
- 570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC (2020) (2)
- Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer. (2013) (2)
- SY12-3Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance (2015) (2)
- Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer (2022) (2)
- Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup. (2018) (2)
- Molecular Cancer Therapeutics Synergistic Antitumor Effect of S-1 and HER 2-Targeting Agents in Gastric Cancer with HER 2 Amplification (2010) (2)
- Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study (2022) (2)
- Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023) (2)
- A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study). (2019) (2)
- Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). (2011) (2)
- SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
- Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. (2020) (2)
- Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). (2010) (2)
- Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. (2021) (2)
- A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer (2013) (2)
- Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. (2021) (2)
- Randomized Phase II Study of Adjuvant Chemotherapy with S-1 Versus CDDP + S-1 in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (WJOG4107) (2012) (2)
- Phase I Clinical and Pharmacokinetic Study of RAD 001 ( Everolimus ) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (2)
- Lux-Lung 3: Afatinib Versus Cisplatin and Pemetrexed in Japanese Patients with Adenocarcinoma of the Lung Harboring an EGFR Mutation (2012) (2)
- Low expressions of surfactant-associated protein (SP-A) in cancer tissues or in normal bronchial epithelial cells by immuno-histochemistry predict interstitial lung diseases (ILDs) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC) (2005) (2)
- HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors (2020) (2)
- Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST). (2009) (2)
- Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib (2016) (2)
- Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab (2012) (2)
- P2.03a-056 Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: KTOSG Trial 1301: Topic: Clinical Trials (2017) (2)
- Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. (2022) (2)
- Zoledronic acid-induced regression of multiple metastases at nonskeletal sites. (2009) (2)
- Abstract A241: Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. (2013) (2)
- PLS. plenary session (2012) (2)
- Non-small cell lung cancer, early stage (2012) (2)
- P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib (2021) (2)
- 415OPrevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer (2017) (2)
- Abstract 3858: Synergistic antitumor effects of combination therapy with S-1 and HER2 targeting agents in gastric cancer with HER2 amplification (2010) (1)
- Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004) (2021) (1)
- Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. (2009) (1)
- Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer (2020) (1)
- A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801). (2022) (1)
- Safety and ef fi cacy of weekly nab ®-paclitaxel in combination with carboplatin as fi rst-line therapy in elderly patients with advanced non-small-cell lung cancer (1)
- Abstract 3893: Overexpression of FOXQ1 is important factor in tumorigenicity and tumor growth (2010) (1)
- P-134 Expression of constitutively activated EGFRvIII in non-small cell lung cancer (2003) (1)
- P3.02b-073 A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR): Topic: EGFR Clinical (2017) (1)
- A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L) (2020) (1)
- [Cancer of unknown primary site-current status and future direction]. (2009) (1)
- P3.04-004 Treatment Rationale and Study Design for the TAKUMI Trial (2017) (1)
- Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer. (2013) (1)
- [Three cases of pulmonary aspergilloma treated by cavernostomy and simultaneous removal of fungus balls]. (2009) (1)
- Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors (2021) (1)
- OA03.05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (2021) (1)
- Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer (2019) (1)
- Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients: Preliminary results (2005) (1)
- Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors (2021) (1)
- Large Cell Neuroendocrine Carcinoma of the Mediastinum with -Fetoprotein Production (2008) (1)
- 1285P Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia (2021) (1)
- A randomized phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small cell lung cancer (JCOG1201/TORG1528). (2021) (1)
- Molecular Networks of the EGFR-TKI Resistant Non-Small Cell Lung Cancer: How to Apply New Technologies to Bench-to-Bed Research (2012) (1)
- Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer. (2010) (1)
- Subgroup Analysis of Japanese Patients in a Phase I/III Study of Atezolizumab in ES-SCLC (IMpower133) (2019) (1)
- Phase III Study of Cisplatin Plus Pemetrexed versus Cisplatin Plus Vinorelbine for Completely Resected Stage II-IIIA Non-Squamous Non-Small-Cell Lung Cancer: The JIPANG Study (2019) (1)
- OA03.05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (2021) (1)
- Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study (2022) (1)
- [Dedifferentiated Chondrosarcoma of the Chest Wall]. (2016) (1)
- Combination therapy with molecularly targeted agents in lung cancer. (2017) (1)
- Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer (2020) (1)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (1)
- 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib (2022) (1)
- P1.07-014 Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers (2017) (1)
- [A case of xanthogranulomatous pyelonephritis probably derived from a renal injury]. (1987) (1)
- Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. (2007) (1)
- P1.07-014 Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers (2017) (1)
- A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small-Cell Lung Cancer (2012) (1)
- Title Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer : updated results of the West Japan Oncology Group (2018) (1)
- SY3-2CONTINUATION MAINTENANCE FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER(NSCLC) (2014) (1)
- Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer (2021) (1)
- [A case of dermatomyositis becoming symptomatic after recurrence of small cell lung cancer]. (2010) (1)
- P2.03-045 Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR) (2017) (1)
- Phase I dose-escalation and pharmacokinetic study of amrubicin in patients with recurrent advanced lung cancer (2005) (1)
- Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation (2011) (1)
- H14Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) (2015) (1)
- Abstract 1231: Differential roles of trans-phophorylated EGFR, HER2, HER3 and RET as heterodimerization partenrs of MET in lung cancer with MET amplification (2012) (1)
- Heregulin as a novel cetuximab-resistace factor in colorectal cancer. (2010) (1)
- Patient-oriented optimal depth of conscious sedation using midazolam during flexible bronchoscopy: A prospective open-labeled single-arm trial. (2018) (1)
- 9117 POSTER Randomized Phase II Trial of Zoledronic Acid in Combination With Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients With Bone Metastases – Result of a West Japan Oncology Group Study (2011) (1)
- Characteristics of smoking lung cancer patients with emphysematous bullae. (2016) (1)
- OA02.06 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L) (2019) (1)
- Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation (2012) (1)
- A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study). (2022) (1)
- 351OInduction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer (2015) (1)
- Overexpression of FOXQ1 is Important Factor in Tumorigenecity and Tumor Growth (2012) (1)
- 1536TiPAn open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer (2017) (1)
- Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non–small cell lung cancer (2013) (1)
- Scedosporium apiospermum lung disease in a patient with nontuberculous mycobacteria (2020) (1)
- Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR). (2014) (1)
- IS4. Trials in Progress (2012) (1)
- Multi-institutional phase II study of carboplatin-gemcitabine combination chemotherapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) (2007) (1)
- Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations. (2013) (1)
- Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer (2021) (1)
- A phase I dose-escalating study of combination S-1 and carboplatin (CBDCA) in patients with chemo-naïve advanced non-small cell lung cancer (NSCLC). (2006) (1)
- Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study (2022) (1)
- P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC. (2016) (0)
- Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial (2012) (0)
- 1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L) (2022) (0)
- Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. (2019) (0)
- A phase I/I b study of GSK1120212 (trametinib) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. (2013) (0)
- Abstract 1918: Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM-1 receptor (2021) (0)
- Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients (2020) (0)
- O11-3 Phase 2 trial of atezolizumab with bevacizumab for patients with PD-L1 high non-Sq NSCLC (WJOG10718L/At Be Study) (2021) (0)
- Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (2013) (0)
- Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis (2023) (0)
- Carboplatin and Irinotecan (CI) vs. Carboplatin and Etoposide (CE) for the Treatment of Extended-Stage Small-Cell Lung Cancer in an Elderly Population: A Phase II/III Randomized Control Trial (2023) (0)
- NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration (2020) (0)
- 327 INVITED Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer (2011) (0)
- P3.02c-001 Phase I Study of Salazosulfapyridine Targeting Cancer Stem Cells in Combination with CDDP and Pemetrexed for Chemo-Naïve Advanced Non-Sq NSCLC: Topic: Targeted Therapy (2017) (0)
- IS6-5PHASE I STUDY OF YM155, SELECTIVE SURVIVIN SUPPRESSANT PLUS ERLOTINIB IN PATIENTS WITH EGFR-MUTANT ADVANCED NSCLC (2014) (0)
- Pulmonary Tumor Thrombotic Microangiopathy Caused by a Gastric Cancer (2013) (0)
- Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (2013) (0)
- Afatinib-Induced Bronchiolitis Obliterans (2023) (0)
- O1-9-6A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer (2015) (0)
- P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients with Locally Advanced NSCLC (2018) (0)
- Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma (2022) (0)
- Pleuroparenchymal fibroelastosis secondary to autologous peripheral blood stem cell transplantation: A case report (2023) (0)
- A phase II study of cisplatin plus S-1 in patients with carcinomas of unknown primary site. (2011) (0)
- Abstract 1918: Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM-1 receptor (2021) (0)
- 1233PSAFETY DATA ANALYSES FOR FIRST-LINE PEMETREXED PLUS CARBOPLATIN (PEM + CB) IN NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC). (2014) (0)
- P-0118 Chemotherapy with Cpt-11 After Gemcitabine Failure in Patients with Advanced Pancreatic Cancer (2012) (0)
- Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non small cell lung cancer (NSCLC) (2004) (0)
- 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study (2022) (0)
- P1.14-03 Phase II Trial of Amrubicin and Cisplatin Chemotherapy for Invasive Thymoma: WJOG5509L (2018) (0)
- Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study. (2023) (0)
- P1.08-006 Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC (2017) (0)
- O1-9-2TUMOR GENOMIC PROFILING OF NSCLC FROM THE PHASE III TRIAL OF FIRST-LINE S-1/CBDCA VERSUS PACLITAXEL/CBDCA (WJOG6611LTR) (2014) (0)
- 13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis (2022) (0)
- Pleuroparenchymal fibroelastosis secondary to autologous peripheral blood stem cell transplantation: A case report (2023) (0)
- Case report Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer (2003) (0)
- 9072 Phase II study of amrubicin (AMR) in patients (pts) with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy, a further analysis on adverse effect: WJTOG0401 (2009) (0)
- IS7. lung cancer (2012) (0)
- Activin-A Directly Inhibits Vascular Endothelial Cell Growth VIA TGF-b-Dependent Signal Pathway (2012) (0)
- 484PDA multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer (2015) (0)
- Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer (2013) (0)
- Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases. (2012) (0)
- IS10 3 PDGF-CC: A THERAPEUTIC TARGET IN BREAST CANCER (2012) (0)
- FUNCTIONAL ANALYSIS OF MOB1 IN RESECTABLE LUNG ADENOCARCINOMA (2018) (0)
- Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial (2022) (0)
- Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events (2021) (0)
- PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF TUMOR LOCATION IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ANTI-PD-1 THERAPY (2020) (0)
- 40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC (2023) (0)
- O1–104PHASE I PHARMACOKINETIC STUDY OF S-1 GRANULE AND NEDAPLATIN FOR PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK CANCER (2013) (0)
- Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts). (2010) (0)
- P1.03-004 Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (2017) (0)
- MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L) (2021) (0)
- Phase II study of irinotecan and S-1 combination therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): (WJTOG3505) (2008) (0)
- Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired (2013) (0)
- Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial. (2023) (0)
- A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC) (2019) (0)
- IMMUNOLOGICAL ANALYSIS OF PLEURAL EFFUSION IN CANCER PATIENTS WHO RECEIVED IMMUNE CHECKPOINT INHIBITORS (ICI) FOR THE DEVELOPMENT OF BIOMARKERS (2018) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- Osimertinib failure followed by successful treatment of afatinib in a patient with compound uncommon, G719S and V834L mutations. (2023) (0)
- Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial (2021) (0)
- Making death good: a study of terminal cancer patients in Japan (2003) (0)
- Metastatic Lung Adenocarcinoma Mimicking Meningioma (2017) (0)
- Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study (2022) (0)
- Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (0)
- 329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib (2022) (0)
- 1261PCOMPARISON OF OUTCOMES BETWEEN RESPONDERS AND NONRESPONDERS TO FIRST-LINE PACLITAXEL/CARBOPLATIN (P/C) DOUBLET CHEMOTHERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (0)
- Abstract 1095: Short Poly A sequence in HGF promoter region is involved in overexpression of HGF in cancer cells (2011) (0)
- P3.02b-097 Experience of Re-Biopsy (Biopsy at Progression) of EGFR Mutant Non-Small Cell Lung Cancer Patients in Japan: A Retrospective Study: Topic: EGFR RES (2017) (0)
- Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003) (2022) (0)
- Abstract 2545: Roles of BIM induction and survivin down-regulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011) (0)
- O2-3-5Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L): a randomized phase II trial (2015) (0)
- Cell cycle regulation and radiosensitization of TZT-1027, a novel antimicrotubule agent (2006) (0)
- OA23.06 Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients (2017) (0)
- 1259 POSTER A Phase II Study of Cisplatin Plus S-1 in Patients With Carcinomas of Unknown Primary Site (2011) (0)
- A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) (2020) (0)
- 1140P Validation of a deep learning model for the classification of lung cancer in a large cohort of biopsied samples (2021) (0)
- A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study (2022) (0)
- 9120 POSTER Linifanib Plus Carboplatin/Paclitaxel (CP) in Japanese Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) -Phase 1 Preliminary Results (2011) (0)
- Molecularly-targeted Therapies for Advanced Non-small-cell Lung Cancer (2019) (0)
- Tyrosine phosphoproteomics identified both co-drivers and co-targeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer RUNNING TITLE: Phosphoproteomics of EGFR-TKI resistance (2014) (0)
- Development of Systemic Musculoarticular Sarcoidosis 30 Years After Onset of Cutaneous Sarcoidosis (2019) (0)
- Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma (2022) (0)
- Afatinib-Induced Bronchiolitis Obliterans (2023) (0)
- Multicenter cooperative observational study of idiopathic pulmonary fibrosis with non-small cell lung cancer (2016) (0)
- Osimertinib failure followed by successful treatment of afatinib in a patient with compound uncommon, G719S and V834L mutations. (2023) (0)
- Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients (2020) (0)
- Phase II study of amrubicin (AMR) in patients (pts) with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: WJTOG0401. (2009) (0)
- Oral S-1 and Carboplatin Plus Bevacizumab with Maintenance S-1 and Bevacizumab for Chemo-Naïve Patients with Non-Squamous Non-Small-Cell Lung Cancer (2012) (0)
- PD4-2-2: Phase II study of irinotecan and S-1 combination therapy in patients (pts) with advanced non-small cell lung cancer (NSCLS): results of West Japan Thoracic Oncology Group trial (WJTOG3505) (2007) (0)
- P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan (2022) (0)
- A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study (2022) (0)
- Abstract 1736: Src inhibitor dasatinib enhances anti-tumor activity of irreversible or T790M-selective epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer cells with T790M gate-keeper mutation (2011) (0)
- Abstract 4922: NEUROD1 is highly expressed in extensive small cell lung cancer by promoting migration (2020) (0)
- Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE) (2023) (0)
- Association of the Expression of Mutant EGFR Protein as Determined with Mutation-Specific Antibodies in NSCLC Cancer Patients (2012) (0)
- Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS). (2018) (0)
- Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study. (2021) (0)
- P3.09-15 Genetic Profiling of Idiopathic Pulmonary Fibrosis Associated Non-Small Cell Lung Cancer by Targeted Next-Generation Sequencing (2018) (0)
- Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis. (2009) (0)
- Neural stem cell specific ITPA deficiency causes depolarization of neurons, resulting in epileptic seizure and early death in mice (2019) (0)
- Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer (2022) (0)
- P12.02 Systemic Anticancer Therapy Upregulate Plasma Levels of Damage-Associated Molecular Patterns in Patients With Advanced Lung Cancer (2021) (0)
- P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC (2017) (0)
- Influence of ITPA-deficiency on mammalian cells and mouse central nerve system (2016) (0)
- Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study. (2021) (0)
- Relationship between EGFR protein expression, EGFR gene amplification, EGFR gene mutations and gefitinib sensitivity in human non-small cell lung cancer cell lines (2006) (0)
- Postprogression Survival for Advanced NSCLC (2012) (0)
- 1208 POSTER Phase I and Pharmacokinetic Study of the Angiogenesis Inhibitor TSU-68 Combined With Carboplatin Plus Paclitaxel in Patients (pts) With Advanced Non-small-cell Lung Cancer (NSCLC) (2011) (0)
- P1.01-34 Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L) (2018) (0)
- Required Capabilities and Infrastructure for Japanese Phase I Institutes: From the Experience of Early Phase Drug Development Operation at Phase I Centers in United States (2012) (0)
- O3-15-3HEREGULIN AS A BIOMARKER FOR ANTI-HER3 ANTIBODY PATRITUMAB COMBINED WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER (2014) (0)
- The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L). (2019) (0)
- P3.04-002 A Randomized Phase II Study of Carboplatin plus Nab-Paclitaxel with or Without Nintedanib for NSCLC with IPF (J-SONIC): Trial in Progress (2017) (0)
- Highly sensitive and quantitative detection of EGFR T790M mutationin tumor samples by nanofluidic digital PCR. (2014) (0)
- Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer (2014) (0)
- Abstract CT067: Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study (2023) (0)
- HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors (2019) (0)
- 394PA new tool to visualize and quantificate activated epidermal growth factor receptor homodimerization with proximity lagation assay in lung cancer (2017) (0)
- P3.09-15 Genetic Profiling of Idiopathic Pulmonary Fibrosis Associated Non-Small Cell Lung Cancer by Targeted Next-Generation Sequencing (2018) (0)
- P2-304: Multi-institutional phase ii study of carboplatin/gemcitabine combination chemotherapy in elderly patients (Pts) with advanced non-small cell lung cancer (NSCLC) (2007) (0)
- Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L). (2019) (0)
- Abstract 4446: Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer. (2013) (0)
- Abstract 4922: NEUROD1 is highly expressed in extensive small cell lung cancer by promoting migration (2020) (0)
- Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases (2022) (0)
- Genetic Pro fi ling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA (2019) (0)
- non-small cell lung cancer, early stage 1179O THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT: A WAY TO BRIDGE NON-SMALL CELL LUNG CANCER MOLECULAR CHARACTERISTICS AND CLINICAL DATA (2012) (0)
- Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases (2023) (0)
- 723 POSTER A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors (2007) (0)
- OS1. gastric cancer (2012) (0)
- P-0117 Second-Line Chemotherapy with S-1 after Cisplatin and Gemcitabine Failure in Patients with Advanced Biliary Tract Cancer (2012) (0)
- MIS2. lung cancer clinical (2012) (0)
- Randomized Phase II Trial of Zoledronic Acid in Combination with Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (NSCLC) Patients with Bone Metastases: WJTOG3806 (2012) (0)
- Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. (2022) (0)
- Postprogression Survival for First-Line Chemotherapy in Patients with Advanced Gastric Cancer (2012) (0)
- [Molecular-targeted drug for non-small cell lung cancer]. (2012) (0)
- FP14.02 A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC (2021) (0)
- Dying my own way: a study of terminal cancer patients in Japan (2002) (0)
- Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR) (2020) (0)
- Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small-Cell Lung Cancer Haboring Activating EGFR Mutation (WJOG6410L) (2012) (0)
- Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. (2023) (0)
- Successful Treatment with Corticosteroid in a Case of Elderly Severe Pulmonary Sarcoidosis Progressing to Acute Respiratory Failure (2018) (0)
- IS10. breast cancer translational study (2012) (0)
- Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study (2022) (0)
- 62P Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small cell lung cancer patients (2022) (0)
- Abstract 2412: Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment (2020) (0)
- Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. (2022) (0)
- 1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors (2009) (0)
- [II. Development and Future Prospects of the Third-Generation EGFR-Tyrosine Kinase Inhibitor]. (2015) (0)
- Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer (2007) (0)
- P2.13-18 A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing (2018) (0)
- [Molecular targeting therapy for treatment of non-small-cell lung carcinoma]. (2008) (0)
- Clinical benefits associated with first line treatment using afatinib (2015) (0)
- O3-12-3SURVIVAL OUTCOME ASSESSED ACCORDING TO TUMOR RESPONSE AND SHRINKAGE PATTERN IN EGFR(+)NSCLC TREATED WITH EGFR-TKI (2014) (0)
- 6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407 (2021) (0)
- Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment. (2022) (0)
- Lung Cancer: Driver Oncogene and Molecular-Targeted Therapies (2012) (0)
- Abstract 3733: Heregulin as a novel resistant factor for cetuximab (2010) (0)
- P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era (2021) (0)
- 740 Cytogenetic analysis in advanced colorectal cancer (1995) (0)
- P2.15-004 Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528) (2017) (0)
- [Erlotinib in non-small cell lung cancer]. (2011) (0)
- NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration (2020) (0)
- Retraction (2021) (0)
- Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer. (2014) (0)
- Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). (2013) (0)
- Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts). (2016) (0)
- Abstract 2412: Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment (2020) (0)
- Phase 1 study on safety and PK of rovalpituzumab tesirine (Rova-T) in Japanese patients with advanced, recurrent SCLC. (2018) (0)
- 5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer (2017) (0)
- Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP) (2012) (0)
- JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status (2019) (0)
- Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment. (2022) (0)
- Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial (2022) (0)
- MA13.06 Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L) (2019) (0)
- Abstract 424: Amplification ofOCT4-pseudogenePOU5F1Bis a poor prognostic factor in gastric cancer (2012) (0)
- 1662P Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay (2021) (0)
- MIS4. lung cancer basic (2012) (0)
- Biomarker-Driven Treatment Strategies for Non-Small-Cell Lung Cancer (2012) (0)
- Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma (2012) (0)
- Abstract 5596: Dynamic monitoring of plasma DAMP proteins during multimodal anticancer treatment in advanced lung cancer patients (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Isamu Okamoto?
Isamu Okamoto is affiliated with the following schools:
